Stryker Corporation vs Atlassian Corporation PLC — how do they compare? Stryker Corporation trades at $276.85 (market cap $106.24B), while Atlassian Corporation PLC trades at $204.59 (market cap $51.53B). The key difference: Stryker Corporation is far larger — about 2.1× Atlassian Corporation PLC's market cap, and Stryker Corporation pays a 1.27% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and Atlassian Corporation PLC for 64 Days on average.
| SYK | TEAM | |
|---|---|---|
Market Cap | $106.24B | $51.53B |
Volume | 2,982,001 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $388.35 | $203.57 |
52-Week Low | $269.75 | $57.15 |
Typical Hold Time | 20 Days | 64 Days |
Enterprise Value | $117.70B | $51.52B |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical momentum and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $1.87 exceeding expectations. Revenue growth remains robust at $5.22B in 2025, though profitability challenges persist with negative net margins. Recent news highlights AI-driven growth catalysts and cloud migration success.
Outlook remains positive with 69.77% analyst buy ratings and $191.16 consensus target. Key opportunities include $140B addressable market and AI adoption, while risks involve negative profitability metrics and high valuation multiples. The stock faces execution risk in maintaining growth momentum amid competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →